Remdesivir: A Comprehensive Guide

Remdesivir, marketed under the brand name Veklury, is an antiviral medication initially developed to combat Ebola virus. It has since grow a key treatment option for COVID-19, receiving FDA approval for specific uses and emergency authorization for others. This article provides a detailed overview of remdesivir, covering its approved uses, dosage, potential side effects and vital considerations for healthcare professionals, and patients.

What is Remdesivir?

Remdesivir is a nucleotide analog that inhibits viral RNA polymerase, an enzyme crucial for viral replication. By interfering with this enzyme, remdesivir effectively slows down the spread of the virus within the body. It is administered intravenously (IV).

Approved Uses by the FDA

As of October 2020, the FDA has approved remdesivir for the treatment of COVID-19 in hospitalized adults and children 12 years and older. Since January 2022, it has similarly been authorized for emergency use in certain outpatient and pediatric populations. Specifically, remdesivir is indicated for:

• Hospitalized Adults and Children (12+ years): Treatment of COVID-19 requiring hospitalization.
• Non-Hospitalized Patients at High Risk: A 3-day course of remdesivir may be considered for patients with mild to moderate COVID-19 symptoms who are at high risk of progressing to severe disease, hospitalization, or death.

Severe disease is defined as:

• SpO2 ≤ 94% on room air
• Requiring supplemental oxygen
• Requiring mechanical ventilation
• Requiring extracorporeal membrane oxygenation (ECMO)

Dosage Information

Dosage varies depending on whether the patient is hospitalized or being treated as an outpatient:

Hospitalized Patients

A typical 5-day course involves:

• 200 mg IV once, followed by
• 100 mg IV every 24 hours for 4 days.

The duration can be extended to an additional 5 days if there is no clinical response, or to 10 days for patients requiring mechanical ventilation and/or ECMO. Studies have indicated a higher rate of serious adverse events with a 10-day treatment compared to a 5-day treatment, though clinical outcomes were not significantly different in patients not on ECMO or mechanical ventilation.

Non-Hospitalized Patients

A 3-day course consists of:

• 200 mg IV on day 1, followed by
• 100 mg IV on days 2 and 3.

Potential Side Effects

Remdesivir can cause side effects, some of which may require immediate medical attention. It is crucial to monitor patients closely during and after administration.

Serious Side Effects: Seek emergency medical help if you experience signs of an allergic reaction, such as:

• Hives
• Difficulty breathing
• Swelling of the face, lips, tongue, or throat

Other side effects may occur during or after the injection.

Important Considerations

Before administering remdesivir, healthcare professionals should visually inspect the solution for particulate matter and discoloration. Remdesivir is manufactured by Gilead Sciences Inc. And is available in 100 mg vials, with an average wholesale price of $685.78 per vial.

Disclaimer

This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.